Gracell Biotech's Multiple Myeloma Candidate Shows 100% Response Rate In Newly Diagnosed Candidates

  • Gracell Biotechnologies Inc GRCL announced the clinical data from its ongoing Phase 1 investigator-initiated trial (IIT) in China evaluating GC012F as first-line therapy in transplant-eligible, high-risk, newly diagnosed multiple myeloma (NDMM) patients. 
  • Patients in the study achieved a 100% overall response rate (ORR) and 100% minimal residual disease (MRD) negativity in all dose levels.
  • Related: Gracell Biotech Stock Has Over 100% Upside On Next-Gen CAR-T Platforms, Analyst Claims.
  • Among the 16 evaluable patients with a median follow-up time of eight months. 100% of evaluable patients achieved MRD negativity in all dose levels.
  • 100% of patients experienced robust CAR-T cell expansion with long persistence in all dose levels
  • The clinical data also demonstrated a favorable safety profile.
  • 25% (4/16) of patients experienced Grade 1-2 cytokine release syndrome (CRS); no patients experienced Grade 3-5 CRS
  • No immune effector cell-associated neurotoxicity syndrome or other neurotoxicity of any grade had been observed.
  • Price Action: GRCL shares are down 3.39% at $2.43 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!